e-Therapeutics Appoints Daniel Elger as Chief Financial Officer
News Jul 21, 2011
e-Therapeutics plc has announced that Dr Daniel Elger will be joining the Company and its Board as Chief Financial Officer, with immediate effect.
Dr Elger, 41, was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc. He joined that company in 2002 and served on its Senior Management Team from 2005, playing significant roles in corporate strategy, fundraisings and the acquisition of two US biotech companies.
He also directed the investor relations strategy for the Company. Before Antisoma, Daniel was a Programme Director for major pharmaceutical companies at a leading marketing and communications agency. He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University.
Malcolm Young, e-Therapeutics Chief Executive said, “Daniel has a wide set of skills across corporate, financial and communications areas, and he is a valuable addition to the e-Therapeutics team. Following our £21m placing at the beginning of the year, implementing our strategic plans and communicating them to current and potential shareholders will be key elements of his role. We look forward to working with him.”
There is no other information that is required to be disclosed with regards to the above mentioned appointment pursuant to Schedule 2 paragraph (g) of the AIM Rules.
We announce the departure of Mr J.M. Cordiner from his position as Finance Director of e-Therapeutics plc and from the Board on 10 June 2011 in order to pursue other business interests. Oliver James, Non-Executive Chairman of e-Therapeutics said: "e-Therapeutics thanks Johnny for his services and wishes him well in his new business ventures."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE